# AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

> **NCT05850234** · PHASE1,PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 182 (estimated)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** AZD0120

## Key facts

- **NCT ID:** NCT05850234
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-20
- **Primary completion:** 2027-08-31
- **Final completion:** 2028-11-14
- **Target enrollment:** 182 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05850234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05850234, "AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05850234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*